Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
The Ankyrin-G protein encoded by the ANK3 gene functions to immobilize the backbone protein on the cell membrane. As an important linker protein, ankyrin plays an important role in a variety of biological activities. Recent studies have found that ankyrin may be involved in cell signal transduction and apoptosis, and participate in several key links in the process of signal transduction. At the same time, a number of genome-wide association studies (GWAS) in recent years have also suggested that the ANK3 gene and its encoded ankyrin are closely related to mental diseases, especially schizophrenia, and bipolar disorder.
ANK3 and Bipolar Disorder
Bipolar disorder is a psychiatric disorder characterized by manic episodes and depression, and its pathogenesis is not yet clear. In recent years, a variety of factors with complex functions and located upstream of the regulatory mechanism have become research hotspots, such as brain-derived nerve growth factor (BDNF) and Ankyrin-G. In a number of GWAS studies on the two-way affective disorder, it was also found that ANK3 gene single nucleotide polymorphism sites (SNPs) rs10994336, rs1938526, and rs10994415 were associated with the disease. Therefore, the role of the ANK3 gene in the pathogenesis of bipolar disorder has received more attention.
The scientists then used molecular genetics techniques to conduct a more in-depth study of the gene. The association of two variant sites of ANK gene with bipolar disorder was repeated to verify the rs10994336 locus found by GWAS. A meta-analysis was used to further demonstrate that the ANK3 gene may be a risk gene for bipolar disorder. Ament et al. found that the gene may affect the excitability of neurons through rare mutations, thereby increasing the risk of bipolar disorder. Although a large number of studies have repeatedly verified that several sites discovered by GWAS are closely related to the onset of bipolar disorder, the specific biological mechanism remains unclear. Subsequently, at the transcriptional level, after silencing the expression of ANK3 gene, the initial segment of the axon of the nerve cell disappears and is replaced by a dendritic structure, which may be the basis for brain structural changes in patients with the bipolar disorder caused by ANK3 gene.
Figure 1. Model of the molecular signature of (A) BD-related pathophysiology and (B) lithium׳s mechanism of action in Ank3+/− mice. (Gottschalk, et al. 2017).
Bavamian's other study on small RNA (microRNA) found that enhanced miR-34a expression regulates ANK3 and CACNB3 genes and impairs neural differentiation, synaptic protein expression, and neuromorphology, thereby reducing endogenous miR- 34a expression and enhancing the evolution of dendrites. It further illustrates the molecular regulation mechanism of ANK3 gene triggering brain structural changes in bipolar disorder.
With the development of brain imaging technology, scientists have carried out imaging studies of brain structures and functions related to this gene. Subsequently, Delvecchio et al. repeated the above two SNPs of ANK3 in patients with bipolar disorder and healthy people. Study on the clinical symptoms, carrying the risk allele of the people of Hamilton Depression Scale (HDRS), Young Mania Rating Scale (YMRS) and Brief Psychiatric Rating Scale (BPRS) scores were higher than those in healthy controls. In the cognitive function assessment, the above two alleles did not affect the general intelligence and response time scores of different groups. In imaging, healthy individuals with the rs10994336 risk allele showed reduced activity in the lateral temporal cortex and the middle and lower temporal cortex in the white matter-related activity test. In contrast, in the healthy individuals carrying the rs9804190 risk allele, the activity of the lateral prefrontal cortex and the mid-media and the inferior frontal increased.
ANK3 and Major Depressive Disorder
Experiments have shown that glutamatergic synapses are inextricably linked to the occurrence of a variety of neuropsychiatric diseases. The loss of synapses and the decrease in their plasticity are more inseparable from the onset of affective disorders. At the same time, through the study of the hippocampus in patients with post-mortem depression, the regulation of glutamate-related genes on synapses was also found. With the development and application of technologies such as RNA interference, gene knockout, and superresolution imaging, Smith et al. discovered the regulation of ANK3 on glutamatergic synaptic structure and function. Thus, it is proved that the ANK3 gene may be associated with the onset of depressive disorder. However, at present, the research on ANK3 gene and major depressive disorder is rarely reported.
Frazier et al. selected gene SNPs with high correlations between synaptic function and affective disease: ANK3 (rs10994336), BDNF (rs6265), CACNA1C (rs1006737) and DGKH (rs1170191) for clinical symptoms, cognitive function levels, and brain imaging research. No positive results associated with the ANK3 gene were found. Although there are few studies on the role of ANK3 gene in the pathogenesis of depressive disorder, the relationship between ANK3 and major depressive disorder is worthy of further investigation due to the important role of Ankyrin-G in signal transduction, neurogenesis, and synaptic plasticity.
References:
Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.
Inquiry
Copyright © Creative Biogene. All rights reserved.